Reference : Prevention of early postmenopausal bone loss by strontium ranelate: The randomized, t...
Scientific journals : Article
Human health sciences : Endocrinology, metabolism & nutrition
http://hdl.handle.net/2268/1996
Prevention of early postmenopausal bone loss by strontium ranelate: The randomized, two-year, double-masked, dose-ranging, placebo-controlled PREVOS trial
English
Reginster, Jean-Yves mailto [Université de Liège - ULg > Département des sciences de la santé publique > Epidémiologie et santé publique >]
Deroisy, Rita mailto [Centre Hospitalier Universitaire de Liège - CHU > > Médecine de l'appareil locomoteur >]
Dougados, M. [> > > >]
Jupsin, Isabelle mailto [Centre Hospitalier Universitaire de Liège - CHU > > Médecine de l'appareil locomoteur >]
Collette, Julien mailto [Université de Liège - ULg > > Chimie médicale >]
Roux, C. [> > > >]
Dec-2002
Osteoporosis International
Springer-Verlag London Ltd
13
12
925-931
Yes (verified by ORBi)
International
0937-941X
Godalming
[en] bone mineral density ; menopause ; osteoporosis ; prevention ; strontium ranelate
[en] Early postmenopausal women (n = 160) were randomised to receive placebo or strontium ranelate (SR) 125 mg/day, 500 mg/day or 1 g/day for 2 years (40 participants per group). All participants received calcium 500 mg/day. The primary efficacy parameter was the percent variation in lumbar bone mineral density (BMD), measured using dual-energy X-ray absorptiometry. Secondary efficacy criteria included hip BMD and biochemical markers of bone turnover. At month 24, SR I g/day significantly increased lumbar BMD compared with placebo [mean (SD) +5.53% (5.12); p < 0.001] for measured values and [mean (SD) + 1.41% (5.33%); p < 0.05] for values adjusted for bone strontium content. The annual increase for adjusted values was +0.66% compared with -0.5% with placebo, with an overall beneficial effect after 2 years of about 2.4% with SR I g/day relative to placebo. There were no other significant between-group differences in adjusted lumbar BMD. Femoral neck and total hip BMD were also significantly increased at month 24 with SR I g/day compared with placebo [mean (SD): +2.46% (4.78) and +3.21% (4.68), respectively; both p < 0.001)]. SR 1 g/day significantly increased bone alkaline phosphatase at all time points (p < 0.05) compared with baseline and between-group analysis showed a significant increase, compared with placebo, at month 18 (p = 0.048). No effect on markers of bone resorption was observed. SR was as well tolerated as placebo. The minimum does at which SR is effective in preventing bone loss in early postmenopausal non-osteoporotic women is therefore 1 g/day.
http://hdl.handle.net/2268/1996

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Restricted access
Prevention of early postmenopausal bone loss by strontium ranelate The randomized, two-year, double-masked, dose-ranging, placebo-controlled PREVOS trial.pdfNo commentaryPublisher postprint116.35 kBRequest copy

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.